Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03044600 · ClinicalTrials.gov registry record
Gene Expression in Hyperparathyroidism
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- 22
- Enrollment target
NCT03044600: Clinical Trial study, sponsored by M.D. Anderson Cancer Center.
NCT03044600 is a clinical trial that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03044600 was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- 22 participants
- Enrollment target
Study Summary
Objectives: 1. To better define the differences in molecular genetics of parathyroid tumors in patients with MEN1, single gland parathyroid disease in patients less than 50 years old and single gland disease in patients greater than 50 years old. 2. To better define the incidence of HRPT2 mutation in young patients with primary hyperparathyroidism and determine whether routine testing in these patients is indicated.
Primary Outcome
RNA isolated from banked frozen tissues. cDNA microarray prepared using an Illumina array chip. Results analyzed using Ingenuity analysis software to detect 2-fold changes in gene expression. T-statistics used to determine significantly discriminating genes.
Interventions
- OTHER Chart Review
- OTHER HRPT2 Mutation Evaluation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2012-11-07 |
| Est. Completion | 2017-10-18 |
Why NCT03044600 stopped before completion
NCT03044600 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Chart Review is the first listed.
NCT03044600 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03044600 about?
NCT03044600 is a clinical study titled "Gene Expression in Hyperparathyroidism". Objectives: 1. To better define the differences in molecular genetics of parathyroid tumors in patients with MEN1, single gland parathyroid disease in patients less than 50 years old and single gland disease in patients greater than 50 years old. 2. To better define the incidence of HRPT2 mutation ...
What is the current status of trial NCT03044600?
This trial is currently terminated. The enrollment target is 22 participants. The study started on 2012-11-07. Estimated completion is 2017-10-18.
What interventions are being tested in trial NCT03044600?
The interventions under investigation include: Chart Review (OTHER), HRPT2 Mutation Evaluation (OTHER).
Who is sponsoring clinical trial NCT03044600?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI